Review PROCESS, decision making PROCESS and communication BY
|
|
- Jeffry Nash
- 6 years ago
- Views:
Transcription
1 Review PROCESS, decision making PROCESS and communication BY ethics committee Dr. Reneega Gangadhar, Professor & Head Department of Pharmacology Govt. Medical college Trivandrum
2 Outline Review process Meeting requirements for review Elements of review Decision making process Communication from EC to Principal investigator DCGI Participant Reporting timelines of SAE
3 The Twin Pillars of Protection in Biomedical Research
4 Does this research study have adequate concern for the safety and welfare of its participants? REVIEW PROCESS
5 Review Process Scientific evaluation before ethical review Method of review should be stated in the SOP All reviewers Primary reviewers EC should approve proposals before initiating the study Ethical review through formal meetings and decision not through circulation of proposals
6 REVIEW PROCESS- BEFORE MEETING The member secretary shall screen the proposals for their completeness Based on the risk involved categorize them into three types exemption from review expedited review and full review
7 Exemption from Review Studies which present less than minimal risk to subjects do not require review Whether a proposal is exempt from review or not is decided by EC and not by the investigator
8 Expedited Review Process Expedited review is done by the Member secretary and Chairperson/member nominated by the Chairperson Minutes of expedited review is ratified in full review If consensus is not reached the Chairperson reverts the study back for a full review
9 Administrative amendments for expedited review Inclusion or deletion of name/s of coinvestigator(s) Request for change in PI or hand over of trials/ projects Minor amendments in the protocol, CRF Change in contact details of PI and EC Chairperson/member secretary provisionally approve & decision ratified at next full review
10 Full Review - Meeting Requirements ECs should meet regularly on scheduled dates Meetings should be planned according to the workload EC members should be given sufficient time for reviewing the relevant documents
11 Full Review - Meeting Requirements The investigator may be invited to present the protocol or provide clarifications in the meeting or respond to queries raised by committee Subject experts could be invited They should not take part in decision making process
12 Full Review During Meeting Review new proposals Evaluate annual progress of ongoing projects and final reports of all protocols Review serious adverse event (SAE) report
13 Elements of Review During Meeting Scientific Design and Conduct of the Study Selection of participants & their protection Informed consent process Protection of their privacy & confidentiality Community considerations
14 Scientific Design and Conduct of Study The appropriateness of study design methodology sample size calculation The justification of Risk benefit ratio Use of control arms
15 Selection of Participants Purpose of equitable participant selection is to ensure Distributive justice : risks of research are spread out over groups of individuals who are expected to benefit from the findings EC will scrutinize eligibility criteria and recruitment methods
16 Protection of Research Participants EC should ensure the suitability of the investigator(s) s qualifications and experience
17 Protection of Research Participants EC should ensure risks to participants are justified & minimized if possible expected benefits, any undue inducement provisions for compensation in SAE /treatment in case of injury clearances from regulatory authorities DCGI, BARC etc. Registration in CTRI
18 Protection of Research Participants Conduct continuing reviews of ongoing trials at intervals For continued protection of the rights and welfare of research subjects. address a wide range of issues new information which may affect participants no. of participants enrolled adverse events reporting protocol deviations need for changes to ICD
19 Protection of Research Participant s Confidentiality Ensure that subjects' privacy & confidentiality are protected to prevent Identification of the participants Especially related to safeguarding research data While publishing data it should be taken care of
20 Informed Consent Process EC should ensure Sufficient information given to participant informed consent is obtained or appropriately waived and documented
21 Community Considerations In order to respect and protect communities EC should examine whether any negative effects on communities such as stigma are minimized ensure promoting positive effects on communities
22
23 DECISION MAKING PRocess A decision should not be kept pending for more than 3-6 months This may be defined in the SOP
24 Decision Making Process Decisions taken preferably by a broad consensus after quorum requirements are fulfilled to recommend recommend with suggestions reject for unethical study When a consensus appears unlikely, then decision may be taken by majority vote
25 Decision Making Process Any conflict of interest (COI) of a member involving a project submitted in writing to the chairperson before review meeting recorded in the minutes If any member has his own proposal for review or has any COI then he should withdraw from EC while the project is being discussed
26 Decision Making Process Only members who review should participate A negative decision should always be supported by clearly defined reason EC may decide to reverse its positive decision on a study if it receives information that may adversely affect the risk/ benefit ratio Analyzes SAE & gives opinion on compensation
27 Decision Making Process EC would order the trial to be discontinued if it finds that the goals of the trial have already been achieved midway or unequivocal results are obtained In case of premature termination of study - reasons Meetings are to be minuted, approved and signed by Chairperson
28 Communication from EC to PI, DCGI, and participant
29 Communication from EC to PI Seek clarifications if any from PI Based on SOP invite PI to present EC should be informed any amendments to protocol /ICD with proper justification protocol deviation/ violations serious and unexpected AEs any new information that may influence study study discontinuation with reasons
30 Communication from EC to PI Member secretary communicates decision in writing within a reasonable time Reasons for rejection Suggestions for modifications, if any If proposal requires waiver of review/ consent
31 Communication from EC to PI The schedule / plan of ongoing review by EC The report of the trial status annually or more frequently if requested Final report on completion/ termination of the project
32 Communication from EC to DCGI EC shall forward its report on serious adverse event to DCGI, after due analysis along with its opinion on financial compensation to be paid by sponsor within 21 days(30 days w.e.f 13 th May 2015) Any change in composition of Ethics Committee Change of PI
33 Communication from EC to Research Participants In the event of written complaint received from patient an expedited or full committee meeting to be held based on the EC SOP Decision taken will be communicated in writing and redressal action taken in consultation with institutional head
34 Communication from EC to Research Participants l When a participant raises doubts about a protocol or its practice... l Answer all the questions honestly and fully, in a language that she/ he can understand
35 Reporting Timelines for SAE Who to Whom? When? Investig ator Spons or EC Investigator Spo nsor EC DCGI, EC, Head of Instituti on Sponsor DCGI, EC, Head of Instituti on DCGI [Chairma n of Exp. Committe e For death case] Initial: <24hr s Full report: within 10/ 14 calend ar days 10/ 14 calen dar days 21/ 30 calen dar days 1/29/
36 Format for Approval of Ethics Committee
37 Format for Approval of Ethics Committee
38 Format for Approval of Ethics Committee
39 Steps In IEC Review
40 Conclusion EC should evaluate the possible risks to the participants These risks should be justified The expected benefits should be looked into EC should evaluate documents to ensure privacy, confidentiality and justice issues
41 Thank You
IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010
IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized
More informationEthics Committees/IRBs Today: Challenges for Efficiency and Quality
Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients
More informationHOSPITAL AUTHORITY (HA) GUIDE
Page 1 of 14 HOSPITAL AUTHORITY (HA) GUIDE ON RESEARCH ETHICS (for Study Site & Research Ethics Committee) Revision Number: 1 (The document supersedes HA RE001 Hospital Authority Guide for Cluster Research
More informationEthics in Biomedical Research
EDUCATIONAL FORUM Ethics in Biomedical Research 1 Vina Vaswani, Vinodkumar C.S 1 2 2 Director, Centre of Ethics, Yenepoya University, Associate Professor, Department of Microbiology S.S Institute of Medical
More informationINSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience
INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing
More informationGood Clinical Practice
Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete
More informationTrends in Oversight of Human Research Protections?
Trends in Oversight of Human Research Protections? Greg Koski, PhD, MD Associate Professor, Harvard Medical School Senior Scientist, James Mongan Institute for Health Policy Former Director, Office for
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationTOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH
Investigators Responsibility #1: Design and Implement Ethical Research Consistent with the Three Ethical Principles Delineated in The Belmont Report. The Belmont Report: Three Basic Ethical Principles:
More informationGood Clinical Practice
Dublin Academic Medical Centre Good Clinical Practice Patrick Murray, MD, FASN, FRCPI Professor, University College Dublin, Mater Misericordiae University Hospital, Dublin, Ireland patrick.murray@ucd.ie
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland Question 1: What laws or regulations apply to an application for conducting a clinical
More informationQuality Assurance in Clinical Trials
Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:
More informationCANCER CENTER SCIENTIFIC REVIEW COMMITTEE
CANCER CENTER SCIENTIFIC REVIEW COMMITTEE The Clinical Scientific Review Committee (SRC) at The Medical College of Wisconsin Cancer Center plays a vital role in protocol review and monitoring to ensure
More informationGovernance Policies for PCORnet, the National Patient-Centered Clinical Research Network
Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network 1.0 Leadership and Decision-Making When reading this document it is important to note that there are several categories
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationWhat is an IRB (Institutional Review Board)?
What is an IRB (Institutional Review Board)? The Belmont Report The Belmont Report on the Ethical Principles and Guidelines for the Protection of Human Subjects of Research was prepared by the National
More informationClinical Research: A Multifaceted Discipline
Clinical Research: A Multifaceted Discipline Anuradha Kulkarni a, Arun Bhatt b* a Senior Associate - Medical & Regulatory Affairs, Clininvent Research Pvt Ltd, A-302, Everest Chambers, Marol Naka, Andheri
More informationRules of Human Experimentation
Rules of Human Experimentation Elaine Larson CUMC IRB Chair Associate Dean for Research, School of Nursing Professor of Epidemiology, Mailman School of Public Health Oversight for Human Research Office
More informationSINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP)
SINGAPORE GUIDELINE FOR GOOD CLINICAL PRACTICE (SGGCP) Date of Implementation: 1 August 1998 Date of First Revision: 1 October 1999 Printed in July 1998, August 1998 and September 1999. Adapted from the
More informationHow did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949
ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are
More informationAPPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD. Revised January 2010 Page 1
APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD Revised January 2010 Page 1 The IRB Proposal Includes: 1. All documents, other than the informed consent form, should be understandable to an informed
More informationSTATE OWNED ENTERPRISES REMUNERATION GUIDELINES
STATE OWNED ENTERPRISES REMUNERATION GUIDELINES PART A CHAIRPERSONS & NON-EXECUTIVE DIRECTORS AUGUST 2007 Restricted Contents 1. DEFINITIONS 3 2. PURPOSE 4 3. GENERAL 4 4. REMUNERATION GUIDELINES 5 5.
More informationWMA Declaration of Helsinki - Ethical
WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects Download the PDF file Adopted by the 18 th WMA General Assembly, Helsinki, Finland, June 1964 and amended
More informationProtection of Research Participants: The IRB Process and the Winds of Change
Protection of Research Participants: The IRB Process and the Winds of Change Ethics in Patient-Oriented Research October 12, 2011 Sharon Friend Director, OHRPP Overview Charge and Function of the IRB Quick
More informationISO INTERNATIONAL STANDARD. Clinical investigation of medical devices for human subjects Good clinical practice
INTERNATIONAL STANDARD ISO 14155 Second edition 2011-02-01 Clinical investigation of medical devices for human subjects Good clinical practice Investigation clinique des dispositifs médicaux pour sujets
More informationExternal IRB Review What Does it Mean for Your Institution
External IRB Review What Does it Mean for Your Institution Wesley G Byerly, Pharm.D. Associate Vice President for Research Integrity and Regulatory Affairs University of Connecticut and UCONN Health HCCA
More informationStreamlining IRB Procedures for Expanded Access
Streamlining IRB Procedures for Expanded Access Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation Richard Klein Director, FDA Patient Liaison Program Office of Health and Constituent Affairs
More informationAgenzia Italiana del Farmaco
Agenzia Italiana del Farmaco The Italian Legislation and the work of the Italian Medicines Agency (AIFA) in the field of ethics of Clinical Trials Umberto Filibeck AIFA Head of GCP Inspectorate and GCP
More informationMRC. Clinical Trials. Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS. Medical Research Council
MRC Clinical Trials Series MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 Medical Research Council MRC GUIDELINES FOR GOOD CLINICAL PRACTICE IN CLINICAL TRIALS 1998 MRC GUIDELINES FOR
More informationInvestigator Manual. Human Subjects Protection Program
Human Subjects Protection Program HRP-103, Revised June 1, 2015 HRP-103 06/01/2015 2 of 33 Table of Contents Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What is the
More informationInstitutional Review Board (IRB)
Institutional Review Board (IRB) Melissa Miklos Program Manager miklosm@upmc.edu Institutional Review Board What is the IRB? Why does the IRB exist? Where is the IRB? Who is the IRB? When do you need the
More informationINVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)
INVESTIGATIONAL DEVICE EXEMPTION APPLICATION IDE Title (if title being used) Name of Sponsor Investigator, MD X Professor, Department Icahn School of Medicine at Mount Sinai Date of Submission Form version
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationISPE Comments on the CIOMS 2006 draft Special Ethical Considerations for Epidemiologic Research 1
Epidemiologic Research 1 December 12, 2006 Comments on 2006 CIOMS draft Special Ethical Considerations for Epidemiologic Research as proposed supplement to the updated 2002 CIOMS International Ethical
More informationTrial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products
1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible
More informationImplementation of the EU-law. Tom Van Paepegem Quality co-ordinator D.R.U.G.
Implementation of the EU-law Tom Van Paepegem Quality co-ordinator D.R.U.G. History (1) World War II: Experiments by Nazi-doctors 1946: Nüremberg process 1947: Nüremberg codeddd History (2) 10 basic ethical
More informationR&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:
Research as a Participating site STANDARD OPERATING PROCEDURE FOR OVERSIGHT SOP No: P08/PF2 V2 Effective Date: 31 st July 2013 Supersedes: P08/PF2 Revision Date: 31 st March 2014 Author: Position: Approved
More informationPK 7.1 QSU 011 E02 PROSEDUR KUALITI PERMOHONAN KELULUSAN ETIKA PERUBATAN
PK 7.1 QSU 011 E02 PROSEDUR KUALITI PERMOHONAN KELULUSAN ETIKA PERUBATAN 1.0 PURPOSE 1.1 This procedure describes the process of review, approval, and continuing review of all clinical trials/studies involving
More informationEthical Principles in Clinical Research
Ethical Principles in Clinical Research Christine Grady NIH Clinical Center Department of Bioethics No conflicts of interest. Views presented are mine and do not necessarily represent positions or policies
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More informationWorld Medical Association Declaration of Helsinki
World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly Helsinki, Finland, June 1964 and amended by the
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015
THE STUDY PROTOCOL The study protocol is a written document detailing how a clinical trial is conducted. The elements of a protocol include: 1. Trial design and organization; 2. Study objectives; 3. Background
More informationINVESTIGATOR HANDBOOK
INVESTIGATOR HANDBOOK INVESTIGATOR HANDBOOK Table of Contents MISSION... 3 FIRST TIME SUBMISSION... 3 EDUCATIONAL REQUIREMENTS... 3 PRINCIPAL INVESTIGATOR NEW STUDY SUBMISSIONS... 4 VULNERABLE POPULATIONS...
More informationRegulatory and ethical requirements in medical device studies. Finland
Regulatory and ethical in medical device studies Finland SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within
More informationHospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)
Page 1 of 8 Hospital Authority (HA) Guide on Research Ethics (for Study Site & Version Effective Date 2 01/02/2015 Document Number HAHO-CE&TM-HA REC Author HA Head Office Steering Committee on Research
More informationGuidelines and Recommendations for European Ethics Committees
Guidelines and Recommendations for European Ethics Committees European Forum for Good Clinical Practice A Place to Meet Revised Edition 1997 All rights in this document are reserved by the, a not-for-profit
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationGUIDELINES ON MEDICAL DEVICES
Ref. Ares(2016)1982736-26/04/2016 EUROPEAN COMMISSION DG Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Health technology and Cosmetics MEDDEV 2.7/3
More informationPre-Screening revised checklist for BA/BE NOC for Export Purpose
Pre-Screening revised checklist for BA/BE NOC for Export Purpose O/o Drugs Controller General (India) Directorate General of Health Services FDA Bhawan, New Delhi (With effective from 25 th April 2014)
More informationMEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155
MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part
More informationGUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN MAKING AN ASSESSMENT OF CLINICAL INVESTIGATION NOTIFICATION
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.2 December 2008 GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN
More informationData Quality and Integrity: From Clinical Monitoring to Marketing Approval
Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November 2010 1 Objectives Identify the importance of accuracy,
More informationInvestigator Manual HRP-103
HRP-103 Revised October 04, 2016 Table of Contents 1. Introduction... 3 A. Scope... 3 B. Purpose of this manual... 3 C. Where to get additional information and answers to questions... 3 E. Human Research
More informationRegulatory and ethics bodies involved in approval process. CA - Submission for authorisation mandatory for
Medicinal Products for Human Use - CZECH REPUBLIC Competent authority Contact Details Contact Name 1 State Institute for Control of Drugs- SÚKL (Státní ústav pro kontrolu léčiv) Phone +420 272 185 111
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationExpanded Access. to Investigational Drugs & Biologics. for Treatment Use
SJMHS Research Compliance Office Guidance Document Expanded Access to Investigational Drugs & Biologics for Treatment Use May 2015 1 Expanded Access to Investigational Drugs & Biologics for Treatment Use
More informationRadiation - Florida Department of Health Institutional Review Board
500-26 Radiation 500-26 Radiation - Florida Department of Health Institutional Review Board Protocol title: Researcher: Application contact: For questions, concerns, to provide input, or request a consultation,
More informationNomination and Remuneration Committee Charter
Charter Nomination and Remuneration Committee Charter Myer Holdings Limited ACN 119 085 602 Myer Holdings Limited PO Box 869J Melbourne VIC 3001 Australia Telephone +61 3 8667 6000 www.myer.com.au Nomination
More informationThe primary purposes of the Corporate Governance Committee shall be to shape the corporate governance of the Company, and by doing so shall:
CONSTELLATION BRANDS, INC. BOARD OF DIRECTORS CORPORATE GOVERNANCE COMMITTEE CHARTER Composition and Member Qualifications The Corporate Governance Committee of the Board of Directors shall be composed
More informationInstitutional Review Board
Institutional Review Board Overview & Minimal Risk Research Jon Mark Hirshon, MD, MPH Vice-Chairman University of Maryland Institutional Review Board May 18, 2006 Jon Mark Hirshon, MD, MPH 1 Presentation
More informationOPTINOSE, INC. CORPORATE GOVERNANCE GUIDELINES
OPTINOSE, INC. CORPORATE GOVERNANCE GUIDELINES The Board of Directors (the Board ) of OptiNose, Inc. (the Company ) has adopted these Corporate Governance Guidelines (these Guidelines ) to assist the Board
More informationQuality Assurance in Clinical Trials Introduction
Quality Assurance in Clinical Trials Introduction Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 2012 1 Delphine TEPPE-CROITROU - Catherine CORNU (Hospices Civils de Lyon)
More informationTHE BIOMEDICAL RESEARCH ETHICS COMMITTEE (BMREC)
UNIVERSITY OF THE WESTERN CAPE THE BIOMEDICAL RESEARCH ETHICS COMMITTEE (BMREC) TERMS OF REFERENCE AND STANDARD OPERATING PROCEDURES UNIVERSITY OF THE WESTERN CAPE BIOMEDICAL RESEARCH ETHICS COMMITTEE
More informationEmbryonic Stem Cell Research Oversight (ESCRO) Committee. Policies and Procedures
University of California, Los Angeles Embryonic Stem Cell Research Oversight (ESCRO) Committee TABLE OF CONTENTS Section Page 1.0 Purpose... 2 2.0 Authority... 2 3.0 Function... 2 4.0 Review... 2 4.1 Review
More information2 : self-directing freedom and especially moral independence 3 : a self-governing state
A Adverse Effect Adverse Event AE Amendment Approve Approve Pending Assent Assurance Authorization Autonomy Unanticipated problem or unfavorable symptom or disease occurring during a clinical study, though
More informationINTEL CORPORATION BOARD OF DIRECTORS GUIDELINES ON SIGNIFICANT CORPORATE GOVERNANCE ISSUES
INTEL CORPORATION BOARD OF DIRECTORS GUIDELINES ON SIGNIFICANT CORPORATE GOVERNANCE ISSUES A. BOARD COMPOSITION 1. Board Leadership; Separation of the positions of Chairman and CEO The Board s general
More informationInstitutional Biosafety Committee
Northern Illinois University Institutional Biosafety Committee Policy Office of Research Compliance, Integrity and Safety 2017 Northern Illinois University Institutional Biosafety Committee Purpose...
More informationREGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL MEDICAL DEVICES DR D DIALE MRS P NKAMBULE. 02 December 2015
REGULATORY REQUIREMENTS FOR CLINICAL TRIAL APPROVAL MEDICAL DEVICES DR D DIALE MRS P NKAMBULE 02 December 2015 LAYOUT Background to clinical trials Stakeholders in clinical trials Legislative requirements
More informationRecommendations for Strengthening the Investigator Site Community
Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials
More informationObjectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder
Essential Documents: Maintaining the Site's Regulatory Binder How to Manage the Essential Documents for the Investigator and Study Site Objectives Describe the importance of maintaining the Regulatory
More informationOVERVIEW OF THE PREQUALIFICATION OF MALE CIRCUMCISION DEVICES ASSESSMENT PROCESS
D i a g n o s t i c s a n d L a b o r a t o r y T e c h n o l o g y OVERVIEW OF THE PREQUALIFICATION OF MALE CIRCUMCISION DEVICES ASSESSMENT PROCESS Prequalification of Male Circumcision Devices PQMC_007
More informationHuman Subjects Protection: Training for Research Teams
Human Subjects Protection: Training for Research Teams Walter L. Calmbach MD MPH South Texas Ambulatory Research Network (STARNet) Dept. of Family & Community Medicine Univ. of Texas Health Science Center
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationSource And Regulatory Documentation for DMID Clinical Studies
Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in
More informationICH Topic E 6 Guideline for Good Clinical Practice NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95) *
The European Agency for the Evaluation of Medicinal Products ICH Topic E 6 Guideline for Good Clinical Practice Step 5, Consolidated Guideline 1.5.96 NOTE FOR GUIDANCE ON GOOD CLINICAL PRACTICE (CPMP/ICH/135/95)
More informationSTANDARD OPERATING PROCEDURES
STANDARD OPERATING PROCEDURES Final, Version 1: 01 March 2012 Pharma-Ethics (Pty)Ltd Registration No. 99/13868/07 PO Box 786 Irene, 0062 123 Amcor Road Lyttelton Manor, 0157 Tel: (012) 6648690 Fax: (012)
More informationSOUTHERN CROWN RESOURCES LIMITED ACN (Company) CORPORATE GOVERNANCE PLAN
SOUTHERN CROWN RESOURCES LIMITED ACN 143 416 531 (Company) CORPORATE GOVERNANCE PLAN TABLE OF CONTENTS SCHEDULE 1 BOARD CHARTER... 1! SCHEDULE 2 CORPORATE CODE OF CONDUCT... 7! SCHEDULE 3 AUDIT AND RISK
More informationRECRUITING OF AND ADVERTISING FOR SUBJECTS
1. POLICY Steering Committee approved 9/19/11 The informed consent process begins when a potential human research subject first learns of a study, which is usually accomplished through recruitment efforts.
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationUniversity of Virginia Cancer Center
University of Virginia Cancer Center Data and Safety Monitoring Plan for Clinical Research March 18, 2016 Approved: National Cancer Institute April 14 th, 2016 Table of Contents 1. Introduction... 3 2.
More informationIBL LTD AUDIT AND RISK COMMITTEE TERMS OF REFERENCE
IBL LTD AUDIT AND RISK COMMITTEE TERMS OF REFERENCE 1. Overall Purpose/Objectives 1.1 The Audit and Risk Committee, while assisting the Board in fulfilling its oversight responsibilities, will also be
More informationFor the purposes of this document, the above statement should be used to guide the reader s understanding of health research.
1 1. THE IMPORTANCE OF ETHICS 1.1 Introduction South Africa is undergoing transformation into a non-racial, non-sexist, democratic state in which human dignity, equality and the advancement of human rights
More informationImpact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004
Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive
More informationMulti-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18
Multi-Site Coordination Process Drafted by: Ester Dimayuga Page 1 of 18 MULTI-SITE COORDIATIO (MSC) REGULATOR PROCESS CTO-Regulatory notifies MSC of trial with UMCC as coordinating center MSC prepares
More informationHANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP)
HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) GUIDANCE FOR IMPLEMENTATION HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) GUIDANCE FOR IMPLEMENTATION WHO Library Cataloguing-in-Publication Data
More informationInstitutional Review Board Compliance Elizabeth City State University
Institutional Review Board Compliance Elizabeth City State University Michelle Moore, MBA Research Compliance Officer/IRB Administrator Office of Sponsored Programs, Contracts & Grants 110 McLendon Hall
More informationSimonetta Viviani, MD BIO-VIPE Consulting Limited, Hong Kong
Simonetta Viviani, MD BIO-VIPE Consulting Limited, Hong Kong DCVMN Clinical Development & Pharmacovigilance Training 17-21 July 2016, Bali, Indonesia Pratical tips on how to write a protocol Write the
More informationBOARD GUIDELINES ON SIGNIFICANT CORPORATE GOVERNANCE ISSUES
BOARD GUIDELINES ON SIGNIFICANT CORPORATE GOVERNANCE ISSUES Management and the Board of Directors ( Board ) of Nabors Industries Ltd. (the Company ) are committed to conducting business consistent with
More informationNON-PROFIT CORPORATION INFORMATION ORGANIZER
NON-PROFIT CORPORATION INFORMATION ORGANIZER 1400 W. Benson Blvd., Suite 370 Anchorage, AK 99503 907-258-3224 phone 907-258-3229 fax info@durrell.com www.durrell.com NON-PROFIT CORPORATION INFORMATION
More informationPURCHASING & TENDERING PROCEDURES
Purchasing and Tendering Procedures 1. General Overview The Office of the Comptroller ( CO ) is responsible for handling all purchases of goods and services of the University of which this set of purchasing
More informationAUDIT COMMITTEE CHARTER. Specifically, the Audit Committee is responsible for overseeing that:
AUDIT COMMITTEE CHARTER PREFACE The Audit Committee of the Board of Directors shall assist the Board in fulfilling its responsibilities with respect to (1) the integrity of the financial statements of
More informationVolunteering for Clinical Trials
Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked
More informationResearch: Ethics, Informed Consent, FDA, Off Label Use
Research: Ethics, Informed Consent, FDA, Off Label Use Nasim Hedayati, MD, FACS, RPVI Assistant Professor Division of Vascular and Endovascular Surgery University of California, Davis 2015 Phlebology Review
More informationStanford University IRB Guidance On Data and Tissue Repositories
Stanford University IRB Guidance On Data and Tissue Repositories Databases, registries (data banks), and repositories (tissue banks) all involve the collection and storage of information and/or biological
More informationIndivior PLC. Terms of Reference of the Audit Committee. Adopted: November 5, 2014 Last Updated: September 22, 2016 Owner: Company Secretary
Indivior PLC Terms of Reference of the Audit Committee Adopted: November 5, 2014 Last Updated: September 22, 2016 Owner: Company Secretary AUDIT COMMITTEE TERMS OF REFERENCE 1. Purpose and Policy 1.1 The
More informationGOOD CLINICAL PRACTICE (GCP) Series Catalog
GOOD CLINICAL PRACTICE (GCP) Series Catalog CITI Program s GCP series consists of three basic courses and three refresher courses. The basic courses include: GCP for Clinical Trials with Investigational
More informationThe future clinical trial authorisation process: the new evaluation process
The future clinical trial authorisation process: the new evaluation process Massimiliano Sarra March 20 th 2017 Public Declaration of transparency/interests* The view and opinions expressed are those of
More information